-
...van der Linden <i>et al.</i>, 1999</a>), high solubility (Arbabi Ghahroudi M. et al, 1997) and very few cleavage sites for enzymes allow new areas of a
...el, Oliver; Wojcik, John; Kaupe, Ines; Kovacic, Boris; Wyrzucki, Arkadiusz M. et al. (2011): Targeting the SH2-kinase interface in Bcr-Abl inhibits leuk
16 KB (2,252 words) - 03:24, 20 October 2016
-
equipment. Finally, we thank Dr. Mark Forsyth, Dr. Helen Murphy, Dr. Bev Sher, and Dr. Doug Young for their
...<b>2.</b> Sun, Z. Z., Yeung, E., Hayes, C. A., Noireaux, V., & Murray, R. M.Linear DNA for rapid prototyping of
10 KB (1,232 words) - 03:53, 20 October 2016
-
...ov, Julie E. Norville, Christopher J. Gregg, Barry L. Stoddard, and George M. Church. "Corrigendum: Biocontainment of Genetically Modified Organisms by
...r, Ph.D., Michael Rodemeyer, J.D., Michele S. Garfinkel, Ph.D., and Robert M. Friedman, Ph.D. (2014). Synthetic Biology and the US Biotechnology Regulat
5 KB (662 words) - 02:05, 20 October 2016
-
...<a href="#Blank" style="padding-left: 1.8cm;" class="bgscroll" >Prof. Lars M. Blank</a></p>
<b>Dr. Helen Rosenkranz</b>, for a lot of organizational work and fund administration. <
48 KB (6,501 words) - 12:58, 19 October 2016
-
...ref="#Blank" style="padding-left: 1.8cm;" class="bgscroll" >Prof. Dr. Lars M. Blank</a></p>
<b>Dr. Helen Rosenkranz</b>, for a lot of organizational work and fund administration. <
48 KB (6,542 words) - 15:54, 3 December 2016
